Abstract Objective To compare the levels of short-chain fatty acids in enterobacteria-related metabolites in feces between infants with cholestatic hepatopathy and healthy infants. Methods Thirty infants with cholestatic hepatopathy were enrolled in this study as the disease group, while 30 healthy infants were enrolled as the control group. Fecal specimens were collected from the disease group before and after treatment and from the control group. Gas chromatography was used to quantitatively determine the content of short-chain fatty acids in the feces of both groups including acetic acid, propionic acid, butyric acid, isobutyric acid, and isovaleric acid. Results There were no significant differences in the concentrations of acetic acid and propionic acid between the control and disease groups before and after treatment, as well as no significant changes in the two markers in the disease group after treatment (P > 0.05). The disease group had a significantly increased concentration of butyric acid after treatment (P < 0.05). The concentrations of isobutyric acid and isovaleric acid in the control group were significantly higher than those in the disease group before and after treatment (P < 0.05). Conclusions Intestinal protein metabolites in infants with cholestatic hepatopathy are significantly different from those in healthy infants, whereas there is no significant difference with respect to carbohydrate metabolites.
Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants:joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2017, 64(1):154-168.
McCoy KD, Ignacio A, Geuking MB. Microbiota and type 2 immune responses[J]. Curr Opin Immunol, 2018, 54:20-27.
Komaroff AL. The microbiome and risk for atherosclerosis[J]. JAMA, 2018, 319(23):2381-2382.
Zuo T, Kamm MA, Colombel JF, et al. Urbanization and the gut microbiota in health and inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7):440-452.
Adolph TE, Grander C, Moschen AR, et al. Liver-microbiome axis in health and disease[J]. Trends Immunol, 2018, 39(9):712-723.
Gonçalves P, Araújo JR, Di Santo JP. A cross-talk between microbiota-derived short-chain fatty acids and the host mucosal immune system regulates intestinal homeostasis and inflammatory bowel disease[J]. Inflamm Bowel Dis, 2018, 24(3):558-572.
Sun M, Wu W, Chen L, et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis[J]. Nat Commun, 2018, 9(1):3555.
Fushimi T, Tayama K, Fukaya M, et al. Acetic acid feeding enhances glycogen repletion in liver and skeletal muscle of rats[J]. J Nutr, 2001, 131(7):1973-1977.
Tong LC, Wang Y, Wang ZB, et al. Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress[J]. Front Pharmacol, 2016, 7:253.
Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function[J]. Cell Host Microbe, 2015, 17(5):662-671.
Smith EA, Macfarlane GT. Dissimilatory amino acid metabolism in human colonic bacteria[J]. Anaerobe, 1997, 3(5):327-337.